These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29635632)

  • 61. Controlled trial of morphine vs hydromorphone for patient-controlled analgesia in children with postoperative pain.
    Karl HW; Tyler DC; Miser AW
    Pain Med; 2012 Dec; 13(12):1658-9. PubMed ID: 23013512
    [No Abstract]   [Full Text] [Related]  

  • 62. Hydromorphone: pharmacology and clinical applications in cancer patients.
    Sarhill N; Walsh D; Nelson KA
    Support Care Cancer; 2001 Mar; 9(2):84-96. PubMed ID: 11305075
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Oral oxycodone: new preparation. No better than oral morphine.
    Prescrire Int; 2003 Jun; 12(65):83-4. PubMed ID: 12825566
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
    Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Resolution of Intrathecal Hydromorphone or Morphine-induced Peripheral Edema by Opioid Rotation to Fentanyl: A Case Series.
    Veizi E; Tornero-Bold M; Hayek SM
    Pain Pract; 2016 Jul; 16(6):E94-8. PubMed ID: 26990069
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prospective investigation of intravenous patient-controlled analgesia with hydromorphone or sufentanil: impact on mood, opioid adverse effects, and recovery.
    Yang Y; Wu J; Li H; Ye S; Xu X; Cheng L; Zhu L; Peng Z; Feng Z
    BMC Anesthesiol; 2018 Apr; 18(1):37. PubMed ID: 29636011
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.
    Hale ME; Nalamachu SR; Khan A; Kutch M
    J Pain Res; 2013; 6():319-29. PubMed ID: 23658495
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
    Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative efficacy of opioids for older adults presenting to the emergency department with acute pain: Systematic review.
    de Vries M; Gravel J; Horn D; McLeod S; Varner C
    Can Fam Physician; 2019 Dec; 65(12):e538-e543. PubMed ID: 31831503
    [TBL] [Abstract][Full Text] [Related]  

  • 70. OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs.
    Coluzzi F; Mattia C
    Minerva Anestesiol; 2010 Dec; 76(12):1072-84. PubMed ID: 21102402
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites.
    Smith MT
    Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):524-8. PubMed ID: 10874511
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [New Level III opioids of the World Health Organization].
    Laval G; Sang B; Mallaret M; Villard ML
    Rev Med Interne; 2002 Jan; 23(1):55-70. PubMed ID: 11859695
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Neuraxial opioids for post-cesarean delivery analgesia: can hydromorphone replace morphine? A retrospective study.
    Marroquin B; Feng C; Balofsky A; Edwards K; Iqbal A; Kanel J; Jackson M; Newton M; Rothstein D; Wong E; Wissler R
    Int J Obstet Anesth; 2017 May; 30():16-22. PubMed ID: 28185794
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.
    Huhn AS; Strain EC; Bigelow GE; Smith MT; Edwards RR; Tompkins DA
    Anesthesiology; 2019 Jan; 130(1):131-141. PubMed ID: 30418214
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
    Hale M; Khan A; Kutch M; Li S
    Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Use of hydromorphone (Dilaudid) and morphine for patients with hepatic and renal impairment.
    Razaq M; Balicas M; Mankan N
    Am J Ther; 2007; 14(4):414-6. PubMed ID: 17667220
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
    Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
    Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride.
    Katcher J; Walsh D
    J Pain Symptom Manage; 1999 Jan; 17(1):70-2. PubMed ID: 9919868
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics.
    Han HS; Lee KH; Lee KH; Ryu JS; Kim YC; Park SW; Oh HS; Park KT; Kwon JH; Lee PB; Lee WS; Kim YS; Ahn JB; Jeon SW; Lee SY; Seol YM; Kang JH; Yuh YJ; Oh SY; Kim SR; Ahn JS
    Support Care Cancer; 2014 Mar; 22(3):741-50. PubMed ID: 24203087
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Current Practice of Opioid for Cancer Dyspnea: The Result From the Nationwide Survey of Japanese Palliative Care Physicians.
    Yamaguchi T; Matsunuma R; Suzuki K; Matsuda Y; Mori M; Watanabe H
    J Pain Symptom Manage; 2019 Oct; 58(4):672-677.e2. PubMed ID: 31201876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.